Psoriasis and COVID-19 Infection Negatively Impact Each Other: An Analysis of 3581 Cases

Figures & data

Table 1 Demographic Characteristics of Subjects

		Subjects without Psoriasis (N=2515)	Subjects with Psoriasis (N=1066)	P value
Age (yr)	Females	1237, 49.04 ± 0.52, 32	516, 48.82 ± 0.80, 31	NS
	Males	1278, 48.52 ± 0.52, 32	550, 47.66 ± 0.77, 31	NS
BMI	Females	1237, 21.84 ± 0.12, 7.84	516, 20.07 ± 0.12, 3.95	<0.0001
	Males	1278, 21.98 ± 0.12, 7.76	550, 24.35 ± 0.15, 5.11	<0.0001
COVID Infection	Females	970/1237, 78.42%	464/516, 89.92%	<0.0001
	Males	990/1278, 77.46%	491/551, 89.11%	<0.0001
COVID Vaccination	Females	1079/1237, 87.23%	444/516, 86.05%*	NS
	Males	1102/1278, 86.23%	495/550, 90.00%	=0.026
	Overall	2181/2515, 86.72%	939/1066, 88.09%	NS

Notes: Data are expressed as N, mean ± sem, Interquartile Range (IQR) or N/total, %; Either Fisher’s exact test or unpaired Student’s t-test was used to determine significances. *p=0.0476 vs males.

Table 2 Characterization of COVID Infection in Subjects with vs without Psoriasis

Clinical Symptoms	Non-Psoriasis (N=2515)	Psoriasis (N=1066)	P value
Low Fever (≤38°C)	978/1959, 49.92%	439/955, 45.97%	=0.0484
High Fever (>38°C)	820/1959, 41.86%	450/955, 47.12%	=0.0077
Sore Throat	848/1959, 43.29%	418/955, 43.77%	=0.8113
Coughing	1178/1959, 60.13%	497/955, 52.04%	<0.0001
Fatigue	760/1959, 38.85%	357/955, 37.38%	=0.4650
Headache	836/1959, 42.67%	359/955, 37.59%	=0.0091
Joint and Muscle Pain	708/1959, 36.14%	312/955, 32.67%	=0.0687
Loss of Taste	392/1959, 20.01%	218/955, 22.83%	=0.0810
Diarrhea	185/1959, 9.44%	101/955, 10.58%	=0.3531
Chest Tightness	214/1959, 10.92%	111/955, 11.62%	=0.5731
Chest Pain	150/1959, 5.36%	66/955, 6.91%	=0.1103
Palpitation	221/1959, 11.28%	86/955, 9.01%	=0.0624
Shortness of Breath	150/1959, 7.66%	116/955, 12.15%	=0.0001

Note: Fisher’s exact test was used to determine significances between psoriasis and non-psoriasis.

Table 3 Comparison of Psoriatic Individuals with vs without COVID Infection

	Subjects without COVID (N=111)	Subjects with COVID (N=955)	P values
Age
Females	52, 48.67 ± 2.38, 33.25	464, 48.84 ± 0.85, 31	NS
Males	59, 47.66 ± 2.35, 33	491, 47.66 ± 0.82, 31	NS
Overall	111, 48.14 ± 1.67, 32	955, 48.23 ± 0.59, 31	NS
BMI
Females	52, 19.50 ± 0.33, 3.22	464, 20.13 ± 0.13, 4.05	NS
Males	59, 24.14 ± 0.45, 5.93	491, 24.38 ± 0.15, 5.05	NS
Overall	111, 21.97 ± 0.36, 6.29	955, 22.32 ± 0.12, 5.14	NS
COVID Vaccination	79/111, 71.17%	860/955, 90.05%	<0.0001
Psoriasis Relapse/Worsening	53/111, 47.75%	719/955, 75.29%	<0.0001
Biologics
TNFα	29, 26.13%	223, 24.44%	NS
IL-17α	28, 25.23%	219, 22.93%	NS
IL-23	4, 3.60%	10, 1.05%	=0.0490
IL-22/23p40	3, 2.70%	28, 2.93%	NS
TNFα + IL-17α	15, 13.51%	159, 16.65%	NS
TNFα + IL-23	1, 0.9%	7, 0.73%	NS
TNFα + IL-22/23p40	1, 0.9%	18, 1.88%	NS
IL-17α + IL-23	1, 0.9%	6, 0.63%	NS
IL-17α + IL-22/23p40	1, 0.9%	7, 0.73%	NS
IL-17α + IL-23+ IL-22/23p40	1, 0.9%	0	NS
TNFα + L-17α + IL-23	0	18, 1.88%	NS
TNFα + IL-23+ IL-22/23p40	0	2, 0.20%	NS
Other Combination	0	19, 1.99%	NS
Total	84, 75.68%	716, 74.97%	NS

Note: Except data of biologics, all other data are expressed as N, mean, Interquartile Range (IQR, or ratio, percentage).